Description
Oxaliplatin (OXA) is the third-generation platinum anti-tumor drug after cisplatin and carboplatin. Oxaliplatin was jointly developed by Sanofi and Debiopharm for the first-line treatment of metastatic colon cancer and the adjuvant treatment of stage III colon cancer after complete resection of the primary tumor. It was approved to enter the Chinese market in 1999. By the end of 2020, there are nearly 20 manufacturers in China’s Oxaliplatin market of which Sanofi-Aventis France has the largest market share.
According to CRI’s market research, the sales value of Oxaliplatin in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 epidemic on the hospital’s overall diagnosis and treatment services, the sales value of Oxaliplatin in the Chinese market decreased to CNY1.165 billion in 2020. The CAGR of Oxaliplatin’s sales value in the Chinese market from 2016 to 2020 was 4.29%.
CRI expects that Oxaliplatin sales will have a restorative growth in 2021-2025 as the alleviation of the COVID-19 epidemic. In 2020, the number of new colon cancer cases in China was 550,000, with an increase of 46.28% from 376,000 in 2018. Therefore, Oxaliplatin sales will increase from 2016 to 2020 with the increase in the number of colon cancer patients.
Topics Covered:
-The impact of COVID-19 on China’s Oxaliplatin market
– Sales value of China’s Oxaliplatin 2016-2020
– Competitive landscape of China’s Oxaliplatin market
– Prices of Oxaliplatin in China
– Prices of Oxaliplatin in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Oxaliplatin market
– Prospect of China’s Oxaliplatin market from 2021 to 2025